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Objective. Several alterations ofmagnesiummetabolismhave been associatedwith type 2
diabetes pathophysiology, a condition particularly frequent in older persons. We aimed to
evaluate serum total (Mg-tot) and serum ionized magnesium (Mg-ion) in older persons with
type 2 diabetes in order to explore clinically applicable methods for the detection of
magnesium deficit.
Material/Methods. Mg-tot and Mg-ion were measured in 105 fasting subjects with type 2
diabetes (mean age: 71.1 ± 0.8 years; M/F: 45/60) and in 100 age-matched non-diabetic
control persons (mean age: 72.2 ± 0.8 years; M/F: 42/58).
Results. Mg-ion concentrations were significantly lower in diabetic persons compared
with controls (0.49 ± 0.05 mmol/L vs. 0.55 ± 0.05 mmol/L; p < 0.001). Mg-tot was also slightly
but significantly lower in diabetic patients (0.82 ± 0.007 mmol/L vs. 0.84 ± 0.006 mmol/L;
p < 0.05). There was an almost complete overlap in the values of Mg-tot in older diabetic
patients and controls; conversely, 44.8% of diabetic patients had Mg-ion values below
0.47 mmol/L, while none of the controls did. After adjustment for age, sex, BMI, and
triglycerides, Mg-tot was significantly associated with FBG in all the participants (p < 0.05)
and Mg-ion was significantly associated with FBG in all the participants (p < 0.01) and with
HbA1c in diabetic participants (p < 0.001).
Conclusions. Alterations of magnesium serum concentrations are common in type 2
diabetic older adults; Mg-ion evaluation may help to identify subclinical magnesium
depletion (i.e. in patients with normal Mg-tot); the close independent associations of Mg-tot
and Mg-ion with FBG and with HbA1c reinforce the possible link between magnesium
homeostasis and altered glucose metabolism.
© 2014 Elsevier Inc. All rights reserved.
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1. Introduction
There is compelling evidence suggesting that magnesium
depletion may play a role in the pathophysiology of insulin-
resistanceand/or alteredglucosehomeostasis in type2diabetes
mellitus [1–3]. Magnesium is the secondmost abundant intracel-
lular cation after potassium, and it is involved in a number of
fundamental biochemical processes, comprising all ATP transfer
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reactions. Magnesium ion plays a key role in the regulation of
insulin actions, including insulin-mediated glucose uptake [1].
Type 2 diabetes has been associated with extracellular and
intracellular magnesium depletion. Epidemiologic studies have
found a high prevalence of hypomagnesemia in persons with
type 2 diabetes [4–7], especially in those with poorly controlled
glycemic values [4,5], andwithmicro andmacrovascular chronic
complications [8]. Recently, a closeand independent relationship
of low serum Mg concentrations and ventricular ectopy in
patients with type 2 diabetes has been reported [7]. Hypomag-
nesemia is currently considered an accurate predictor of death
and of progression to ESRD in patients with type 2 diabetic
nephropathy [9,10]. Two meta-analyses of prospective studies
concluded that magnesium intake is inversely associated with
type 2 diabetes [11,12];magnesium intake has been also strongly
and inversely associated with the metabolic syndrome [13,14],
while hypomagnesemia has been independently associated
with the development of impaired glucose tolerance [15]. A
recent study showed a close relationship between the presence
of diabetes and the lower levels of magnesium in obese subjects
who undergo bariatric metabolic surgery [16].
Although the importance of magnesium homeostasis in
glucose metabolism is well appreciated, magnesium metab-
olism has not become the focus of routine attention for the
care of type 2 diabetes patients in the clinical practice. The
main reasons for this include the difficulties in obtaining an
easily available, accurate, and reproducible measure of
magnesium status since the concentrations of total serum
magnesium (Mg-tot), commonly used as an estimation of
magnesium in the clinical practice, are extremely constant
and do not accurately reflect the body magnesium status [1].
Depletion of intracellular as well as of ionized serum
magnesium has been reported in the presence of normal
levels of Mg-tot [17,18]. Because aging represents a major risk
factor for Mg insufficiency [19], it is possible that older diabetic
subjects are at further risk of magnesium deficit, which may
not always be clinically apparent.
The present study was designed to evaluate magnesium
metabolism in older type 2 diabetes patients measuring Mg-tot
and the extracellular free levels of magnesium (Mg-ion) with
a Mg-specific ion-selective electrode (ISE) in order to explore
clinically applicable methods for the detection of magnesium
deficit in older persons with type 2 diabetes.
2. Methods
2.1. Subjects
Two hundred and five older persons (aged ≥ 60 years), 105
type 2 diabetic patients (mean age: 71.1 ± 0.8 years; M/F: 45/60)
and 100 age-matched non-diabetic controls (mean age: 72.2 ±
0.8 years; M/F: 42/58) were consecutively recruited from the
Outpatient Clinic of the Geriatric Unit at the University
Hospital of Palermo, Italy. Anthropometric and laboratory
data includingMg-tot andMg-ionweremeasured (Table 1). All
type 2 diabetic persons recruited for the present study were
recently being diagnosed with diabetes, treated with diet
therapy only and had never been treated beforewith insulin or
hypoglycemic agents. In order to avoid possible interferences
with dietary components and physical exercise that may alter
serum magnesium concentrations, we advised participants
not to modify their dietary and physical activity usual habits
during the study period. None of the patients had been on
diuretic therapy for at least 1 month before the study and
none had significant renal dysfunction, as assessed by serum
creatinine levels and calculated glomerular filtration rate
(GFR) [20].
No differences in age, sex, race, blood pressure levels, GFR,
and body mass index (BMI) were present between the groups
(Table 1). It is well known that alcohol abuse may alter
magnesium metabolism by means of different mechanisms,
i.e. malnutrition, increased urinary magnesium loss, among
others [21]. Therefore, we excluded persons with alcohol
abuse (intended as alcohol consumption higher or equivalent
to more than 1 glass of wine per day) and requested the
participants specifically not to change their usual alcohol
consumption habits since this could affect magnesium
circulating concentrations.
The study was approved by the ethical committee of our
Institution and was conducted in accordance with the
guidelines of the Declaration of Helsinki for human research.
An informed consent was signed by all participants. Exclusion
criteria included: not compensated acute disease, such as
severe congestive heart failure, severe chronic obstructive
pulmonary disease, angina pectoris, acute myocardial infarc-
tion or stroke in the previous 6 months of the study,
severe uncontrolled hypertension (SBP ≥ 180 mm Hg and/or
DBP ≥ 90 mmHg),moderate to severe renal or hepatic disease,
and/or alcohol abuse.
2.2. Magnesium measurements
Blood samples were obtained from participants after they had
fasted for 10 h and after they had been in a sitting or supine
position for 15 min. Serum Mg-tot concentrations were
measured by standard colorimetric techniques with an
Table 1 – Clinical characteristics of study participants.
Parameter Controls type 2 diabetes p
N 100 105
Age (years) 72.2 ± 0.8 71.1 ± 0.8 NS
M/F 42/58 45/60 NS
BMI 28.4 ± 0.9 28.8 ± 1.0 NS
Systolic BP (mm Hg) 145.8 ± 2.1 146.9 ±2.0 NS
Diastolic BP (mm Hg) 75.7 ± 0.9 76.1 ± 1.0 NS
HR (bpm) 74 ± 5.1 76 ± 4.1 NS
GFR (mL/min/1.73 m2) 80.4 ± 2.25 83.3 ± 3.2 NS
FBG (mg/dL) 98.1 ± 1.6 142.6 ± 5.2 p < 0.001
Triglycerides (mg/dL) 113.3 ± 5.2 141.6 ± 8.3 p < 0.01
Mg-tot (mmol/L) 0.84 ± 0.006 0.82 ± 0.007 p < 0.005
Mg-ion (mmol/L) 0.55 ± 0.05 0.49 ± 0.05 p < 0.001
BMI: body mass index; BP: blood pressure; bmp: beats per minute;
GFR: glomerular filtration rate; FBG: fasting blood glucose. Mg-tot:
serum total magnesium; Mg-ion: serum ionized magnesium. To
convert mg/dL of glucose in mmol/L multiply by 0.5551.
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automated chemistry analyzer (ISE 900/ISE 1800 modules of
Modular Analytics SWA Roche Diagnostics Italia, Monza,
Italy). Low magnesium was considered for values below
0.7 mmol/L, as usually accepted [22]. Blood for Mg-ion was
drawn into air-evacuated glass tubes containing an inter-cell
separating matrix. After clotting and centrifugation, the tubes
were inverted and serum was drawn off into a syringe
anaerobically, the latter being capped and stored in a freezer
(0 °C–4 °C) for further analysis. A magnesium ion-selective
electrode (ISE) with a neutral carrier-based membrane (Nova
and Stat Profile 8 Ultra analyzers, Waltham, MA, USA) was
used to measure serum Mg-ion [18,23].
Fig. 1 – Serum ionized magnesium levels (Mg-ion) (Panel A) and serum total Mg (Mg-tot) (Panel B) in normal controls (n = 100)
and in type 2 diabetic older persons (n = 105).
Fig. 2 – Serum ionized magnesium (Mg-ion) in the presence of normal or low serum total Mg (Mg-tot) concentrations in type 2
diabetic older persons (n = 105).
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2.3. Statistical Analyses
Data are expressed as means ± SEM. Analyses of the data
were performed using statistical software GraphPad Prism
(GraphPad Software, San Diego, CA) and SPSS software
package (SPSS, Chicago, IL). Differences between diabetic
and non diabetic participants were assessed with unpaired
t tests for continuous variables and with chi-square for
categorical variables. Differences in proportions according
to magnesium concentration cut-off points were assessed
with chi-square (Fig. 2). Pearson’s correlation coefficients
were used to analyze the linear correlations between
variables (Fig. 3). Multivariate linear regression analysis
was used to examine Mg-ion and Mg-tot as predictors of
FBG or HbA1c after adjustment for age, sex, BMI, and
triglycerides. P values ≤ 0.05 were considered to be statis-
tically significant.
3. Results
Clinical and laboratory data are shown in Table 1. Serum
Mg-ion levels were significantly lower in type 2 diabetic
participants compared with age-matched non-diabetic con-
trol subjects. Serum Mg-ion in diabetic subjects was 0.49 ±
0.05 mmol/L (range 0.32 to 0.65 mmol/L, median 0.49 mmol/L,
25% percentile: 0.44 mmol/L, 75% percentile: 0.53 mmol/L),
while in controls it was 0.55 ± 0.05 mmol/L (range 0.47 to
0.73 mmol/L, median 0.54 mmol/L, 25% percentile: 0.51 mmol/L,
75% percentile: 0.58 mmol/L; p < 0.001).
Mg-tot was also slightly but significantly reduced in
type 2 diabetes patients (0.82 ± 0.007 mmol/L, range 0.66
to 0.99 mmol/L, median 0.82 mmol/L, 25% percentile
0.78 mmol/L, 75% percentile 0.86 mmol/L) vs. controls
(0.84 ± 0.006 mmol/L, range 0.70 to 1.01 mmol/L, median
0.84 mmol/L, 25% percentile 0.80 mmol/L, 75% percentile
0.90 mmol/L, p < 0.05, Fig. 1).
In order to explore the proportion of patients with
differences in the measured concentrations of both, Mg-ion
and Mg-tot, we divided the groups considering the partici-
pants with Mg-tot below or above 0.7 mmol/L (usual conven-
tional cut-off value for considering hypomagnesemia) [22]. We
also divided the groups considering participants with Mg-ion
concentrations below or above 0.47 mmol/L.We used this cut-
off value for Mg-ion because this was the lowest value found
in the non-diabetic controls, allowing us to identify the
fraction of diabetic patients with lower values than the
normal controls, which was in fact the interest of our study.
Forty seven type 2 diabetic participants (44.8%) and none of
the non-diabetic controls had Mg-ion concentrations below
0.47 mmol/L. Twelve diabetic participants (11.4%) with low
Mg-ion had alsoMg-tot below 0.7 mmol/L, while a third (n = 35)
of all diabetic participants had low Mg-ion and Mg-tot higher
than 0.7 mmol/L, which accounts for over half (74.5%) of the
diabetic participants with low Mg-ion (Fig. 2). When these
proportions were compared to those of the non-diabetic
controls, there were significant differences as shown in Fig. 2.
Even if the mean Mg-tot was slightly but significantly lower
in diabetic participants when compared to non-diabetic
controls, the values almost completely overlapped in non-
Fig. 3 – Panel A: Relationship between serum ionized magnesium concentrations (Mg-ion) and fasting blood glucose in all
participants of the study. Panel B: Relationship between serum ionized magnesium concentrations (Mg-ion) and HbA1c in
diabetic participants. Panel C: Relationship between serum total magnesium concentrations (Mg-tot) and fasting blood glucose
in all participants of the study. Panel D: Relationship between serum total magnesium concentrations (Mg-tot) and HbA1c in
diabetic participants.
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diabetic and type 2 diabetes participants (Fig. 1) rendering
Mg-tot a tool with a limited discriminatory value. In fact, the
sensitivity of Mg-tot to detect a low concentration of Mg
(considering Mg-ion as gold standard) in the diabetic partic-
ipants was only 25.5% with a specificity of 98.3%. This means
thatMg-tot is able to identify patientswithout lowMg-ion but
has very modest ability to detect those with low Mg-ion.
A close relationship was found between serumMg-ion and
fasting blood glucose (FBG) (r = 0.381, p < 0.001) (Fig. 3, panel A)
when considering both, diabetic and non-diabetic participants.
When considering only diabetic participants, there was a close
relationship between serum Mg-ion and HbA1c (r = 0.427,
p < 0.001) (Fig. 3, panel B). For Mg-tot, the relationships with
FBG in all the patients (r = 0.202, p < 0.01) and with HbA1c
in diabetic participants (r = 0.285, p < 0.01) were also statis-
tically significant (Fig. 3, panels C and D), with a slightly lower
slope of the curves compared to those of Mg-ion. In order
to explore whether Mg-ion and Mg-tot are independent pre-
dictors of FBG or HbA1c, we performed a multivariate linear
regression of these associations. After adjustment for age, sex,
BMI, triglycerides, and GFR, the close association between
Mg-ion and FBG in all the participants and between Mg-ion
and HbA1c in diabetics remained highly significant (Table 2).
In the fully adjusted model, Mg-tot was also significantly
associated with FBG when considering all the participants,
and it was significantly associated with HbA1c in diabetics
after adjustment for age and sex (Table 3). However, after
adjusting for BMI, triglycerides, andGFR, the relation between
Mg-tot and HbA1c was substantially reduced and no longer
statistically significant (Table 3). After adjustment for con-
founders, there was no significant association between Mg-ion
and Mg-tot with FBG in diabetic participants. This may be
probably due, at least in part, to the high variability of FBG in
diabetic patients.
4. Discussion
Magnesium ion is involved in a wide variety of cellular
processes, many of them critical for glucose and insulin
metabolism [1–3]. Based on this, our group has previously
studied cytosolic free concentrations of magnesium, utilizing
non-invasive nuclear magnetic resonance (31P NMR) tech-
niques, and has reported that type 2 diabetes is associated
with significantly lower intracellular magnesium levels [19,24].
Although spontaneous hypomagnesemia is not an uncom-
mon finding in persons with diabetes and Mg-tot has been
extensively utilized in epidemiological studies, it may not be
helpful for the detection of subclinical magnesium deficit in an
individualbasis,whilemoreprecise techniques, suchas 31PNMR
spectroscopy, remain an expensive research-based tool [1].
Resnick et al. have suggested that Mg-ion may be lower in
type 2 diabetes in a preliminary study with a small group of 22
diabetic patients, even in the presence of a normal Mg-tot. In
that study, intracellular free magnesium measured with 31P
NMR spectroscopywas closely correlatedwithMg-ion, while it
was not significantly related to Mg-tot, suggesting that Mg-tot
may not reflect themagnesium status of the intracellular pool
[18]. Our present data in a larger population significantly
expand previous reports, showing that: a) serumMg-ion levels
and Mg-tot are significantly lower in type 2 diabetic persons
compared with age-matched nondiabetic controls (Fig. 1),
suggesting that in chronic stable type 2 diabetes, a depletion
of extracellular magnesium is present; b) Mg-ion is more
accurate in order to identify magnesium depleted patients,
while the range of Mg-tot values almost completely overlaps
in normal controls and type 2 diabetes patients; c) there is a
significant, independent inverse relationship between fasting
serumMg-ionandMg-totwithglycemic indices (i.e. the lower the
Mg-ion andMg-tot, the higher the FBG andHbA1c (Fig. 2)), which
remains highly significant after adjustment for confounders,
Table 2 –Multivariate linear regressionmodels testing the
relation of Mg-ion with FBG in all participants and of FBG
and HbA1c in diabetic participants.
Fasting blood glucose HbA1c
β SE (β) p β SE (β) p
All participants (n = 205)
Model 1 −290.83 50.71 <0.001
Model 2 −235.07 67.16 0.001
Model 3 −205.33 70.62 0.004
Model 4 −196.80 82.39 0.019
Diabetic participants (n = 105)
Model 1 −134.59 84.78 0.116 −8.38 1.85 <0.001
Model 2 −55.22 110.38 0.619 −8.24 2.49 0.002
Model 3 −44.08 108.0 0.685 8.00 2.52 0.002
Model 4 −55.36 120.6 0.649 −6.08 2.48 0.018
Mg-ion: serum ionized magnesium. SE: standard error; FBG: fasting
blood glucose; GFR: glomerular filtration rate.
Model 1: Mg-ion adjusted for age and sex.
Model 2: model 1 plus adjustment for BMI.
Model 3: model 2 plus adjustment for triglycerides.
Model 4: model 3 plus adjustment for GFR.
Table 3 –Multivariate linear regressionmodels testing the
relation of Mg-tot with FBG in all participants and of FBG
and HbA1c in diabetic participants.
Fasting blood glucose HbA1c
β SE (β) p β SE (β) p
All participants (n = 205)
Model 1 −108.19 46.84 0.022
Model 2 −156.93 65.79 0.019
Model 3 −135.92 66.89 0.044
Model 4 −144.30 80.75 0.039
Diabetic participants (n = 105)
Model 1 −101.73 67.59 0.135 −4.43 1.55 0.005
Model 2 −50.99 97.56 0.603 −3.96 2.34 0.095
Model 3 −31.91 95.63 0.740 −3.61 2.37 0.133
Model 4 −6.37 105.73 0.952 −1.58 2.31 0.496
Mg-tot: Serum total magnesium; SE: standard error; FBG: fasting
blood glucose; GFR: glomerular filtration rate.
Model 1: Mg-ion adjusted for age and sex.
Model 2: model 1 plus adjustment for BMI.
Model 3: model 2 plus adjustment for triglycerides.
Model 4: model 3 plus adjustment for GFR.
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further supporting the link between magnesium and glucose
homeostasis. Although Mg-tot was also slightly but signifi-
cantly lower in type 2 diabetes, the fact that Mg-tot values
almost completely overlap in normal and type 2 diabetes
patients renders thismethod of less value compared toMg-ion,
which was able to detect more accurately the presence of a
magnesium deficiency.
Thesedataverify theoverallnotionthatmagnesiumdeficien-
cyisacommon,ifnotgeneral,featureofthediabeticstate.Among
the causes thatmay favormagnesiumdepletion in diabetes, the
most plausible are low magnesium intake and increased
magnesiumurinary loss. Both hyperinsulinemia [25] and hyper-
glycemia [26] associated with type 2 diabetes may contribute
to magnesium increased urinary excretion, while the reduced
insulin sensitivitymay itself affectmagnesiumtransport.
Magnesium deficiency, which may take the form of a
chronic latent magnesium deficit rather than clinically
evident hypomagnesemia, may have practical significance.
Magnesium depletion has been shown to be associated
with hypertension [27], increased platelet aggregation [28],
endothelial dysfunction [29], cardiac arrhythmias [7,30], and
sudden death [31], all cardiovascular conditions occurring
more frequently in diabetes mellitus.
Magnesium is a critical cofactor for several enzymes and
intracellular reactions regulating glucose metabolism and in
general in all reactions that involve the utilization and
transfer of ATP. Because of its role as part of the activated
Mg–ATP complex required for all of the rate-limiting enzymes
of glycolysis, magnesium regulates the activity of all enzymes
involved in phosphorylation reactions. Magnesium concen-
tration is critical in the phosphorylation of the insulin receptor
tyrosine-kinase as well as all other intracellular protein-
kinases, and all ATP and phosphate transfer-associated
enzymes, such as the Ca-ATPases in plasma membrane and
endoplasmic reticulum. These events may be related to the
development of post-receptorial insulin resistance and de-
creased cellular glucose utilization [1,32,33]. A significant
reduction in these enzymatic activities can be observed at
the range of magnesium values seen in disease states such as
diabetes mellitus [34]. Consistent with the involvement of
magnesium in these regulatory functions, hyperglycemia has
been shown to deplete intracellular free magnesium and to
increase intracellular calcium [35,36]. Magnesium deficiency
has been associated with the development of a proinflamma-
tory state, increased production of free oxygen radicals, and
elevation of intracellular calcium concentrations [1,37–39].
Magnesium is a natural physiological calcium blocker [40]
and may prevent oxygen radical formation by scavenging free
radicals and by inhibiting xanthine-oxidase and NADPH
oxidase [41]. Higher levels of magnesium may improve
intracellular ATP production and glucose utilization, because
magnesium is a cofactor of ATP. Magnesium deficiency may
decrease membrane integrity and membrane function, in-
creasing the susceptibility to oxidative stress, and aging-
related diseases [42]. Diets with low magnesium content
[43,44] as well as low concentrations of serum magnesium
[15,45] were associated with an increased risk for the
development of glucose intolerance and diabetes. Magnesium
intake was found to be inversely correlated to systemic
inflammation and insulin resistance [2,46,47].
The present study has diverse strengths including the fact
that it studies older diabetics, a population that is rapidly
growing worldwide, is generally excluded from clinical
studies, and from which a scarce literature is available. The
data presented are based on several lines of evidence
supporting the alterations of magnesium metabolism in
type 2 diabetes, and even after adjustments for several
relevant confounders the results remained strongly statisti-
cally significant. The study also has some potential limita-
tions. The analyses used cross-sectional data, hence, the
confounding of changes in time cannot be evaluated;
however, the present results have an important applicability
in clinical terms because they show that ionized magnesium
was able to identify older diabetic adults with low concen-
trations of blood magnesium that are not evident with the
only measurement of total magnesium. Because the partic-
ipantswere all Caucasoid and Italian, the present resultsmay
not be applicable for other races and ethnicities, as well as
in younger patients. Future studies are needed in order to
test the applicability of the present results in populations of
diverse races, ethnicity and age.
The translational potential of the present results are
relevant because the detection of hypomagnesemia in pa-
tients with apparently normal serum magnesium is essential
in order to correct the altered magnesium and avoid the
multiple negative consequences of the condition, amply
discussed above. Our results confirm that diabetic patients
are prone to hypomagnesemia; this condition is closely
related with glycated hemoglobin even after adjustment for
relevant confounders; hence, the detection and correction of
altered magnesium may be clinically appropriate. Further-
more, considering all the participants, diabetic and non
diabetic, both ionized magnesium and total magnesium
were significantly associated with fasting glucose after
adjustment for confounders. This supports the importance
of magnesium status on glucose homeostasis.
Altogether, our present results in older diabetic patients
confirm the importance of studying magnesium homeostasis
in patients with type 2 diabetes and suggest that assessment
of Mg-ion, together with Mg-tot, may be of help in the clinical
practice for the detection of magnesium deficits in patients
with type 2 diabetes.
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